Laser Treatment — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Medical laser treatment encompasses a broad family of therapeutic and diagnostic applications that use focused, coherent, monochromatic light beams of a precisely defined wavelength to achieve targeted biological effects in medical and surgical practice. The fundamental scientific principle underpinning all medical laser use is selective photothermolysis, first described by Anderson and Parrish in their landmark 1983 Science paper: each biological chromophore (light-absorbing tissue component) has a characteristic absorption peak at specific wavelengths — haemoglobin (oxy- and deoxy-) absorbs maximally at 418, 542, and 577 nm; melanin absorbs broadly across the UV-visible spectrum with greater relative absorption at shorter wavelengths; water absorbs strongly at 1940–3000 nm. By matching the laser wavelength to the target chromophore's peak absorption, energy is selectively deposited in the target structure with minimal collateral heating of surrounding tissue — provided the pulse duration is shorter than the thermal relaxation time of the target structure. This principle allows, for example, selective destruction of pigmented melanocytic lesions without damaging the epidermis, selective coagulation of haemoglobin-rich blood vessels without damaging the dermis, and precise corneal stromal ablation in LASIK without thermal injury to surrounding corneal tissue. Key clinical laser systems by wavelength include: excimer argon-fluoride laser (193 nm) for ultraviolet corneal stromal ablation in LASIK and LASEK; CO2 laser (10,600 nm) — the workhorse of surgical lasers, absorbed intensely by water in superficial tissue producing precise ablation with 0.1 mm control — for skin resurfacing, laryngeal surgery, and gynaecological procedures; Nd:YAG laser (1064 nm) — deep tissue penetration for vascular lesions, tattoo removal, hair follicle destruction, and prostatic tissue ablation; holmium YAG (Ho:YAG, 2080 nm) — intermediate water absorption for kidney stone fragmentation, BPH enucleation (HoLEP), and laryngeal/airway applications; pulsed-dye laser (PDL, 585/595 nm) — targeting oxyhaemoglobin in dermal blood vessels for port-wine stains, haemangiomas, hypertrophic scars, and telangiectasias; and KTP (532 nm, frequency-doubled Nd:YAG) for mucosal vascular lesions and laryngeal papillomatosis. Each application requires clinician-specific training, certification, and calibration of energy parameters.

Medical laser applications span virtually every clinical specialty, and the appropriate patient and indication are determined by the specific laser system and treating specialist. Ophthalmology: LASIK (laser-assisted in situ keratomileusis) and LASEK/PRK (photorefractive keratectomy) use the 193 nm excimer laser to correct myopia (up to -12 D), hyperopia (up to +6 D), and astigmatism by reshaping the corneal stroma; argon laser photocoagulation treats proliferative diabetic retinopathy and age-related macular degeneration; selective laser trabeculoplasty (SLT) reduces intraocular pressure in open-angle glaucoma; and Nd:YAG laser capsulotomy treats posterior capsule opacification after cataract surgery (the most common laser eye procedure globally). Urology: holmium laser enucleation of the prostate (HoLEP) has become the gold-standard endoscopic treatment for symptomatic BPH, achieving TURP-equivalent symptom reduction with lower blood loss; holmium laser lithotripsy fragmenting and dusting renal, ureteral, and bladder stones achieves stone-free rates of 85–95% for most stone locations. Dermatology: fractional CO2 and erbium:YAG lasers resurface acne and surgical scars, periorbital rhytides, and UV-damaged skin; pulsed-dye laser (PDL) clears port-wine stains, cherry angiomas, and hypertrophic scars; Q-switched Nd:YAG and picosecond lasers remove tattoo pigment; 755 nm Alexandrite and 1064 nm Nd:YAG diode lasers achieve permanent hair reduction. ENT and head and neck surgery: CO2 and KTP lasers are used in microlaryngoscopy for vocal cord lesions and subglottic stenosis; laser tonsillotomy and soft palate laser surgery for snoring are established procedures. Oncology: photodynamic therapy (PDT) with a photosensitising agent activated by 630–700 nm light treats oesophageal cancer, endobronchial lung cancer, bladder cancer, and Barrett's oesophagus with dysplasia. Gynaecology and general surgery: CO2 laser vaporises endometriotic implants laparoscopically with fine precision; laser haemorrhoidectomy (HoLEP for haemorrhoids) is an emerging application.

Laser treatment protocols are highly application-specific, but share common principles of precise parameter calibration and patient preparation. For dermatological applications, topical anaesthetic cream (EMLA — eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is applied under occlusion 60–90 minutes before treatment; nerve blocks or tumescent local anaesthesia are used for more extensive ablative procedures. Skin type assessment using the Fitzpatrick scale (I–VI) is mandatory — darker skin types (IV–VI) have greater melanin content in the epidermis and are at significantly higher risk of post-inflammatory hyperpigmentation or hypopigmentation from wavelengths targeting melanin; safer parameter choices (lower fluence, longer pulse duration, better epidermal cooling) or alternative wavelengths (Nd:YAG 1064 nm over Alexandrite 755 nm for hair removal in darker skin types) are selected accordingly. Epidermal cooling protects the epidermis from thermal damage during treatments targeting sub-epidermal chromophores: cryogen spray cooling (Dynamic Cooling Device — a millisecond burst of cryogen before each laser pulse), contact cooling (chilled sapphire window pressed against skin), or chilled gel reduce epidermal temperature below the injury threshold while the laser pulse reaches the dermal target. For surgical laser applications delivered endoscopically — HoLEP, laser lithotripsy, laryngeal microlaryngoscopy — the laser fibre (200–600 micron core diameter) is introduced through the working channel of a cystoscope, ureteroscope, nephroscope, or rigid laryngoscope under general or spinal anaesthesia, and energy is delivered under direct vision in short, controlled pulses. Laser safety precautions are mandatory in all settings: wavelength-appropriate protective eyewear for all personnel and the patient, laser warning signs outside the treatment room, appropriate laser-resistant endotracheal tubes for airway laser procedures, fire extinguisher availability, and minimum effective FiO2 during airway laser procedures to reduce combustion risk. All laser operators must hold appropriate certification (Laser Safety Officer designation and specific training for the laser class and application).

Laser treatments achieve high success rates across their established indications, supported by robust clinical evidence. Refractive surgery: LASIK and LASEK correct myopia to within ±0.5 D of intended target in over 95% of cases; over 90% of patients achieve 20/20 (6/6) vision or better without spectacles; patient satisfaction consistently exceeds 95% in published series. HoLEP for BPH: International Prostate Symptom Score (IPSS) improvement of 70–85%, maximum urinary flow rate (Qmax) improvement from under 8 mL/sec to over 20 mL/sec, and durable outcomes at 5-year follow-up; blood transfusion required in under 1% versus 5–10% for TURP. Laser lithotripsy: holmium laser achieves stone-free rates of 85–98% for ureteric stones and 75–90% for renal pelvis stones depending on stone size, composition, and location; dusting technique (high-frequency, low-energy pulses) achieves fine powder not requiring basket retrieval. Photocoagulation for diabetic retinopathy: argon laser panretinal photocoagulation (PRP) reduces the risk of severe visual loss by over 50% in eyes with high-risk proliferative diabetic retinopathy and reduces neovascular glaucoma risk. Pulsed-dye laser for port-wine stains: significant lightening in over 80% of treated lesions after multiple sessions (3–10 average), with clearance rates of 40–60% in responsive lesions. Tattoo removal with Q-switched and picosecond lasers: 75–95% ink clearance in most black and dark blue tattoos over 5–15 sessions depending on ink density, colour, and depth. Fractional CO2 laser resurfacing: significant improvement in acne scarring (50–75% improvement in scar appearance) and periorbital rhytides (wrinkle reduction). All applications share the consistent advantages of precision targeting, minimal collateral tissue damage, reduced or absent surgical incisions, and faster recovery compared with open surgical alternatives.

Laser treatment risks are highly application-specific and vary from minimal for non-ablative cosmetic procedures to significant for surgical and ophthalmic applications. Dermatological lasers: post-inflammatory hyperpigmentation (PIH) is the most common adverse effect in skin phototypes IV–VI — appearing as darkening of the treated area from 4–8 weeks and lasting up to 6 months; it is mitigated by pre-treatment with topical hydroquinone 4% for 4 weeks, post-procedure SPF50+ sun protection, and parameter adjustments. Persistent hypopigmentation (lightening) may occur, especially with ablative CO2 lasers and is often permanent. Scarring from ablative lasers is uncommon (under 1%) when technique is correct; herpes simplex virus reactivation in ablative resurfacing causes spreading erosions and scarring if not suppressed with prophylactic acyclovir. Burns from incorrect parameters or inadequate cooling cause blistering, scarring, and dyspigmentation. Ophthalmic lasers — LASIK: dry eye syndrome is the most common complication (10–20%), usually temporary but occasionally persistent; night vision disturbances (halos, starbursts) in 5–10% at 3 months; corneal ectasia (progressive corneal steepening causing irregular astigmatism) is a rare but serious complication (under 0.05%) associated with thin residual stromal bed; undercorrection or overcorrection requiring retreatment occurs in 3–5%. Surgical endoscopic lasers: urethral stricture after HoLEP in 1–3%; retrograde ejaculation in 70–90% (common side effect, discussed pre-operatively); temporary haematuria for 1–2 weeks after laser lithotripsy. Airway laser safety: ignition of the tracheal tube by CO2 or KTP laser in an oxygen-rich environment causes airway fire — a rare but catastrophic complication prevented by laser-resistant tubes, minimum FiO2, and halted laser use during any suspected combustion risk. All personnel in laser treatment rooms must wear wavelength-appropriate optical density-certified safety glasses.

Recovery requirements vary dramatically by laser application and energy delivered. Non-ablative cosmetic laser treatments (vascular, pigmented lesion, hair removal, non-ablative fractional): minor erythema and oedema for 24–48 hours; treated areas may be purpuric (bruised) for 7–10 days after pulsed-dye laser treatment of vascular lesions; normal activities resume immediately; SPF50+ broad-spectrum sunscreen mandatory for 4–8 weeks on treated areas. Ablative laser resurfacing (CO2, erbium:YAG): oozing and crusting for 7–10 days; closed wound care with petrolatum-based ointment; strict sun avoidance for 3–6 months; full skin healing 2–3 weeks; new collagen formation continues for 3–6 months; makeup camouflage from 2 weeks. LASIK and refractive laser surgery: distance vision functional within 24 hours but fluctuating for 1–4 weeks; strict instillation of preservative-free lubricating drops every 1–2 hours for 4 weeks; avoidance of eye rubbing and water ingress for 1 week; contact sport and swimming at 4 weeks; driving when visual acuity is confirmed adequate by the ophthalmic surgeon. HoLEP for BPH: urethral catheter removed at 24 hours (versus 2–3 days for TURP); transient haematuria for 1–2 weeks; post-TURP syndrome rare; irritative voiding symptoms (frequency, urgency) for 4–6 weeks as prostate regenerates mucosal lining; sexual activity deferred 4 weeks. Laser lithotripsy: ureteric stent (if placed) removed by flexible cystoscopy at 2–4 weeks; residual stone fragments pass over 2–4 weeks with high fluid intake (2.5–3 litres daily) and alpha-blocker medication to facilitate passage. Photodynamic therapy (PDT): strict daylight avoidance (complete indoor confinement or full-body light protection garments) for 48–72 hours after systemic photosensitiser (porfimer sodium) administration to prevent severe cutaneous phototoxic burns from ambient visible light; shorter restriction period (24 hours) with topical 5-aminolaevulinic acid (5-ALA) used for superficial skin lesions.